about us


We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor, ME-344, a novel mitochondrial inhibitor, and PWT143, a highly selective PI3K delta inhibitor.
[ Read more ]

latest news

MEI Pharma Reports Updated Results from Phase II Study of Pracinostat and Azacitidine in Elderly Patients with Newly Diagnosed AML
[ June 12, 2015 ] [ Poster ]

MEI Pharma Presents at Bank of America Merrill Lynch Health Care Conference [ Webcast ]

MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies
[ May 4, 2015 ] [ Poster ] [ Abstract ] 
[ Am J Cancer Res ] [ Cancer ]

Annual Review Cover
Click here for our 2014 Annual Review